IP Library Granted Patent US 7,169,559
Granted Patent B2
US 7,169,559 · App. 10/436,805 · Granted Jan 30, 2007

LDL receptor-related proteins 1 and 2 and treatment of bone or cartilage conditions

Assignees: Fonterra Corporate Research and Development Ltd.; NZMP + Health and Nutrition Unit; Auckland Uniservices Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,169,559
App. No.
10/436,805
Granted
Jan 30, 2007
Kind
B2
Abstract

LDL receptor-related proteins 1 and 2 (LRP-1 and LRP-2) and interaction between lactoferrin and LRP-1, LRP-2, or p42/44 MAP kinase in diagnosis and treatment of disorders such as bone or cartilage disorders. Also disclosed are methods of screening for related therapeutic compounds.

Claims (10)

1. A method of identifying a candidate compound for treating a bone condition, the method comprising:

contacting a compound with a cell expressing an LRP-1 gene, and quantifying an expression level of the LRP-1 gene in the cell, wherein the expression level of the LRP-1 gene in the presence of the compound, if different from that in the absence of the compound, indicates that the compound is a candidate for treating a bone condition.

2. The method of claim 1 , wherein the cell is an osteoblast cell, osteoblast-like cell, or osteocyte.

3. The method of claim 2 , wherein the cell is a SaOS-2 cell.

4. The method of claim 1 , wherein the cell is an osteoclast cell.

5. A method of identifying a candidate compound for treating a bone condition, the method comprising:

contacting a compound with a cell expressing an LRP-1 gene encoding an LRP-1 protein, and quantifying an activity of the LRP-1 protein in the cell, wherein the activity of the LRP-1 protein in the presence of the compound, if different from that in the absence of the compound, indicates that the compound is a candidate for treating a bone condition.

6. The method of claim 5 , wherein the cell is an osteoblast cell, osteoblast-like cell, or osteocyte.

7. The method of claim 6 , wherein the cell is a SaOS-2 cell.

8. The method of claim 5 , wherein the cell is an osteoclast cell.

Assignments (2)
CHANGE OF NAME Recorded Oct 30, 2023
From: VENTRIA BIOSCIENCE INC.
To: INVITRIA, INC.
Reel/Frame 065394/0517 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2003
From: REID, IAN REGINALD; CORNISH, JILLIAN; GREY, ANDREW BEVIS; NAOT, DORIT; PALMANO, KAY PATRICIA
To: FONTERRA CORPORATE RESEARCH AND DEVELOPMENT LTD.; NZMP + HEALTH AND NUTRITION UNIT; AUCKLAND UNISERVICES LTD.
Reel/Frame 013855/0553 →
Continuity (3)
Provisional Application 6046341900 · Apr 16, 2003
Provisional Application 6038022700 · May 13, 2002
Related Publication 20040038265A1 · Feb 26, 2004